Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Matthew B. Yurgelun, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Lynch Syndrome Center
  • Senior Physician
  • Assistant Professor of Medicine, Harvard Medical School

Clinical Interests

  • Gastrointestinal cancer
  • Genetic testing and management of hereditary cancer syndromes
  • Lynch syndrome

Contact Information

  • Appointments617-632-2178 (Cancer Genetics and Prevention)
    617-582-7777 (established patients)
    617-632-6835 (Gastrointestinal Cancer)
    617-582-9113 (Lynch Syndrome Center questions and
  • Fax617-632-5370

Board Certification:

  • Internal Medicine
  • Medical Oncology

Fellowship:

  • Beth Israel Deaconess Medical Center, Hematology/Oncology

Residency:

  • Beth Israel Deaconess Medical Center, Internal Medicine

Medical School:

  • Columbia University College of Physicians & Surgeons

Research

Cancer Genetics and Prevention, Gastrointestinal Cancer

Dr. Yurgelun is a gastrointestinal medical oncologist at the Dana-Farber Cancer Institute affiliated with both the Gastrointestinal Cancer Center and the Cancer Genetics and Prevention Program.  He has a longstanding special interest in studying the diagnosis, phenotypes, and management of patients with Lynch syndrome and other hereditary gastrointestinal cancer syndromes. His current research includes studying the benefits and limitations of using widespread multi-gene panel testing – rather than criteria-based targeted genetic testing – in the evaluation of patients at risk for hereditary cancer syndromes.

Correction to: Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al. Fam Cancer. 2021 Apr; 20(2):123.
View in: PubMed

Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al. Fam Cancer. 2021 04; 20(2):121-122.
View in: PubMed

Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology. 2021 Jul; 161(1):143-150.e4.
View in: PubMed

A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-11.
View in: PubMed

Managing gastric cancer risk in lynch syndrome: controversies and recommendations. Fam Cancer. 2021 Feb 21.
View in: PubMed

Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncol Pract. 2021 02; 17(2):e236-e247.
View in: PubMed

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 01 06; 19(1):77-102.
View in: PubMed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11).
View in: PubMed

Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prev Res (Phila). 2021 Feb; 14(2):215-222.
View in: PubMed

Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. J Clin Oncol. 2020 12 01; 38(34):4086-4094.
View in: PubMed

Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. Fam Cancer. 2021 04; 20(2):111-116.
View in: PubMed

Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer. 2020 07; 19(3):223-239.
View in: PubMed

Aspirin for Lynch syndrome: a legacy of prevention. Lancet. 2020 06 13; 395(10240):1817-1818.
View in: PubMed

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020 04; 18(4):380-391.
View in: PubMed

A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Cancer Prev Res (Phila). 2020 03; 13(3):291-298.
View in: PubMed

Correction to: Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk. J Cancer Educ. 2020 Feb; 35(1):204.
View in: PubMed

Identification of Lynch syndrome by microsatellite instability and mismatch repair deficiency testing on colorectal adenomas. Eur J Hum Genet. 2020 03; 28(3):275-276.
View in: PubMed

Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):193-199.
View in: PubMed

Precision Treatment and Prevention of Colorectal Cancer-Hope or Hype? Gastroenterology. 2020 01; 158(2):441-446.
View in: PubMed

Health behaviours and beliefs in individuals with familial pancreatic cancer. Fam Cancer. 2019 10; 18(4):457-464.
View in: PubMed

Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. Clin Gastroenterol Hepatol. 2020 04; 18(4):830-837.e1.
View in: PubMed

Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers. Cancer Epidemiol Biomarkers Prev. 2019 07; 28(7):1246-1251.
View in: PubMed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379.
View in: PubMed

Recent advances in Lynch syndrome. Fam Cancer. 2019 04; 18(2):211-219.
View in: PubMed

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
View in: PubMed

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
View in: PubMed

Multigene panel testing versus syndrome-specific germline testing for inherited cancer risk: 'a somewhat different way'. Per Med. 2019 03; 16(2):83-86.
View in: PubMed

Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology. 2019 05; 156(7):2041-2055.
View in: PubMed

Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights Into an Old Diagnostic Strategy. J Clin Oncol. 2019 02 01; 37(4):263-265.
View in: PubMed

Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2019 01 10; 37(2):153-164.
View in: PubMed

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89.
View in: PubMed

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
View in: PubMed

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. Mod Pathol. 2018 12; 31(12):1882-1890.
View in: PubMed

Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. 2018 07; 8(7):803-811.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:101-109.
View in: PubMed

A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med. 2018 11; 20(11):1324-1327.
View in: PubMed

Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018 05; 68(3):217-231.
View in: PubMed

Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet. 2018 03 01; 102(3):401-414.
View in: PubMed

The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. Ann Intern Med. 2017 12 19; 167(12):884-885.
View in: PubMed

Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. J Clin Oncol. 2017 10 20; 35(30):3375-3377.
View in: PubMed

Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):49-58.
View in: PubMed

Mutational cascades in cancer. Oncotarget. 2017 Jun 27; 8(26):41784-41785.
View in: PubMed

Reply to M.S. Daniels et al. J Clin Oncol. 2017 08 01; 35(22):2588-2589.
View in: PubMed

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
View in: PubMed

Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 04 01; 77(7):1510-1541.
View in: PubMed

Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
View in: PubMed

Historical Perspective on Familial Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2017 Mar; 3(2):192-200.
View in: PubMed

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988.
View in: PubMed

Translating Germline Cancer Risk into Precision Prevention. Cell. 2017 02 09; 168(4):566-570.
View in: PubMed

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
View in: PubMed

"New" Cancer Genes and Inherited Colorectal Cancer Risk: Caveat Emptor. Gastroenterology. 2017 01; 152(1):12-13.
View in: PubMed

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. J Mol Diagn. 2017 01; 19(1):84-91.
View in: PubMed

Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A. 2016 09 27; 113(39):10750-8.
View in: PubMed

Genetic predisposition to colorectal cancer: Implications for treatment and prevention. Semin Oncol. 2016 Oct; 43(5):536-542.
View in: PubMed

Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther. 2016 Jul; 38(7):1600-21.
View in: PubMed

Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? J Clin Oncol. 2015 Oct 01; 33(28):3092-5.
View in: PubMed

Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology. 2015 Sep; 149(3):604-13.e20.
View in: PubMed

Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol. 2015 May; 1(2):214-21.
View in: PubMed

Next-generation strategies for hereditary colorectal cancer risk assessment. J Clin Oncol. 2015 Feb 10; 33(5):388-93.
View in: PubMed

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. Br J Cancer. 2014 Jul 29; 111(3):430-6.
View in: PubMed

Therapy-associated polyposis as a late sequela of cancer treatment. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):1046-50.
View in: PubMed

Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012 Dec; 127(3):544-51.
View in: PubMed

Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila). 2012 Apr; 5(4):574-82.
View in: PubMed

Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res. 2005 Jan; 23(1):203-9.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top